無料セミナー : 2018年11月27日『オンコロジーにおける遺伝子治療・CAR-T細胞療法』 DelveInsight Business Research LLP共同開催

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

注目市場の分析:子宮頸がん

Market Spotlight: Cervical Cancer

発行 Datamonitor Healthcare 商品コード 573573
出版日 ページ情報 英文 34 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.93円で換算しております。
Back to Top
注目市場の分析:子宮頸がん Market Spotlight: Cervical Cancer
出版日: 2018年03月07日 ページ情報: 英文 34 Pages
概要

当レポートでは、子宮頸がんの治療薬市場について分析し、疾患の概要や患者数の推移・見通し、現段階での主な治療法および治験・認可状況、子宮頸がん治療薬市場の動向見通し (今後10年間分)、資本取引の動き、現在開発中の治験の進行状況などを調査しております。

分析のポイント

疾患の背景事情

治療法

  • 手術
  • 放射線治療
  • 化学療法
  • 標的療法

疫学

パイプライン上の医薬品

上市済み医薬品

  • 各国での認証状況

今後の主な動き

ライセンス契約・資産買収取引 (全2件)

母体特許

収益機会

治験情勢

関連分析

  • 処方薬の情報

付録

図表一覧

目次
Product Code: DMKC0180635

This Market Spotlight report covers the cervical cancer market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2016, there were 556,200 incident cases of cervical cancer in females worldwide, and expects that number to increase to 609,500 incident cases by

2025. Incidence cases are highest in Asia, and lowest in the Oceania region. Roche's Avastin (bevacizumab) and Amgen's Mvasi (bevacizumab), which target vascular endothelial growth factor; Novartis's Hycamtin (topotecan hydrochloride), a topoisomerase I inhibitor; and Pinnacle's Photofrin (porfmer sodium), a photodynamic therapy, are the only marketed drugs available for cervical cancer. The majority of the marketed drugs are administered via the intravenous route.

Therapies in mid-to-late-stage development for cervical cancer focus on a variety of targets. The majority of the drugs in mid-tolate-stage development for cervical cancer are administered via the intravenous route, with the remainder being intramuscular, intranasal, subcutaneous, and oral.

High-impact upcoming events for drugs in the cervical cancer space include topline Phase II and Phase III trial results. Licensing and asset acquisition activity involving cervical cancer drugs has been weak during 2012-17, with only 11 deals over this time period. The $727.5m license agreement between Inovio and MedImmune for the exclusive rights to develop and market Inovio's INO-3112 was the largest deal during 2012-17.

The clinical trials distribution across Phase I-IV indicates that the majority of trials for cervical cancer have been in early and midphases of development, with 95% of trials in Phase I-II, and only 5% in Phase III-IV.

The US has a substantial lead in the number of cervical cancer clinical trials globally. The UK leads the major EU markets, while South Korea has the top spot in Asia.

Clinical trial activity in the cervical cancer space is dominated by ongoing trials. AstraZeneca and Roche have the highest number of ongoing clinical trials for cervical cancer, with 11 and eight ongoing trials, respectively.

AstraZeneca leads industry sponsors with the highest number of clinical trials for cervical cancer, followed by Roche.

CONTENTS

5 OVERVIEW

6 KEY TAKEAWAYS

7 DISEASE BACKGROUND

8 TREATMENT

8 Surgery

8 Radiotherapy

8 Chemotherapy

9 Targeted therapy

10 EPIDEMIOLOGY

12 MARKETED DRUGS

14 Approvals by country

17 PIPELINE DRUGS

24 KEY UPCOMING EVENTS

25 LICENSING AND ASSET ACQUISITION DEALS

25 Alligator And Aptevo Seal Immuno-Oncology Pact

25 Advaxis Zips Listeria/Opdivo Combo Straight To Registrational Cervical Cancer Trial

27 PARENT PATENTS

28 REVENUE OPPORTUNITY

29 CLINICAL TRIAL LANDSCAPE

32 BIBLIOGRAPHY

32 Prescription Information

33 APPENDIX

LIST OF FIGURES

  • 11 Figure 1: Trends in incident cases of cervical cancer, 2016-25
  • 17 Figure 2: Pipeline drugs for cervical cancer in the US
  • 17 Figure 3: Pipeline drugs for cervical cancer, by company
  • 18 Figure 4: Pipeline drugs for cervical cancer, by drug type
  • 18 Figure 5: Pipeline drugs for cervical cancer, by drug classification
  • 24 Figure 6: Key upcoming events in cervical cancer
  • 25 Figure 7: Licensing and asset acquisition deals in cervical cancer, 2013-18
  • 27 Figure 8: Parent patents in cervical cancer
  • 29 Figure 9: Clinical trials in cervical cancer
  • 29 Figure 10: Top 10 drugs for clinical trials in cervical cancer
  • 30 Figure 11: Top 10 companies for clinical trials in cervical cancer
  • 30 Figure 12: Trial locations in cervical cancer
  • 31 Figure 13: Cervical cancer trials status
  • 31 Figure 14: Cervical cancer trials sponsors, by phase

LIST OF TABLES

  • 10 Table 1: Incident cases of cervical cancer, 2016-25
  • 13 Table 2: Marketed drugs for cervical cancer
  • 15 Table 3: Approvals by country for cervical cancer
  • 19 Table 4: Pipeline drugs for cervical cancer in the US
  • 28 Table 5: Historical global sales, by drug ($m), 2012-16
  • 28 Table 6: Forecasted global sales, by drug ($m), 2017-22

 

Back to Top